Cargando…

Noonan Syndrome in South Africa: Clinical and Molecular Profiles

Noonan Syndrome (NS) is a common autosomal dominant multisystem disorder, caused by mutations in more than 10 genes in the Ras/MAPK signaling pathway. Differential mutation frequencies are observed across populations. Clinical expressions of NS are highly variable and include short stature, distinct...

Descripción completa

Detalles Bibliográficos
Autores principales: Tekendo-Ngongang, Cedrik, Agenbag, Gloudi, Bope, Christian Domilongo, Esterhuizen, Alina Izabela, Wonkam, Ambroise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477999/
https://www.ncbi.nlm.nih.gov/pubmed/31057598
http://dx.doi.org/10.3389/fgene.2019.00333
_version_ 1783413117444685824
author Tekendo-Ngongang, Cedrik
Agenbag, Gloudi
Bope, Christian Domilongo
Esterhuizen, Alina Izabela
Wonkam, Ambroise
author_facet Tekendo-Ngongang, Cedrik
Agenbag, Gloudi
Bope, Christian Domilongo
Esterhuizen, Alina Izabela
Wonkam, Ambroise
author_sort Tekendo-Ngongang, Cedrik
collection PubMed
description Noonan Syndrome (NS) is a common autosomal dominant multisystem disorder, caused by mutations in more than 10 genes in the Ras/MAPK signaling pathway. Differential mutation frequencies are observed across populations. Clinical expressions of NS are highly variable and include short stature, distinctive craniofacial dysmorphism, cardiovascular abnormalities, and developmental delay. Little is known about phenotypic specificities and molecular characteristics of NS in Africa. The present study has investigated patients with NS in Cape Town (South Africa). Clinical features were carefully documented in a total of 26 patients. Targeted Next-Generation Sequencing (NGS) was performed on 16 unrelated probands, using a multigene panel comprising 14 genes: PTPN11, SOS1, RIT1, A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, SHOC2, and SPRED1. The median age at diagnosis was 4.5 years (range: 1 month−51 years). Individuals of mixed-race ancestry were most represented (53.8%), followed by black Africans (30.8%). Our cohort revealed a lower frequency of pulmonary valve stenosis (34.6%) and a less severe developmental milestones phenotype. Molecular analysis found variants predicted to be pathogenic in 5 / 16 cases (31.2%). Among these mutations, two were previously reported: MAP2K1-c.389A>G (p.Tyr130Cys) and PTPN11 - c.1510A>G (p.Met504Val); three are novel: CBL-c.2520T>G (p.Cys840Trp), PTPN11- c.1496C>T (p.Ser499Phe), and MAP2K1- c.200A>C (p.Asp67Ala). Molecular dynamic simulations indicated that novel variants identified impact the stability and flexibility of their corresponding proteins. Genotype-phenotype correlations showed that clinical features of NS were more typical in patients with variants in MAP2K1. This first application of targeted NGS for the molecular diagnosis of NS in South Africans suggests that, while there is no major phenotypic difference compared to other populations, the distribution of genetic variants in NS in South Africans may be different.
format Online
Article
Text
id pubmed-6477999
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64779992019-05-03 Noonan Syndrome in South Africa: Clinical and Molecular Profiles Tekendo-Ngongang, Cedrik Agenbag, Gloudi Bope, Christian Domilongo Esterhuizen, Alina Izabela Wonkam, Ambroise Front Genet Genetics Noonan Syndrome (NS) is a common autosomal dominant multisystem disorder, caused by mutations in more than 10 genes in the Ras/MAPK signaling pathway. Differential mutation frequencies are observed across populations. Clinical expressions of NS are highly variable and include short stature, distinctive craniofacial dysmorphism, cardiovascular abnormalities, and developmental delay. Little is known about phenotypic specificities and molecular characteristics of NS in Africa. The present study has investigated patients with NS in Cape Town (South Africa). Clinical features were carefully documented in a total of 26 patients. Targeted Next-Generation Sequencing (NGS) was performed on 16 unrelated probands, using a multigene panel comprising 14 genes: PTPN11, SOS1, RIT1, A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, SHOC2, and SPRED1. The median age at diagnosis was 4.5 years (range: 1 month−51 years). Individuals of mixed-race ancestry were most represented (53.8%), followed by black Africans (30.8%). Our cohort revealed a lower frequency of pulmonary valve stenosis (34.6%) and a less severe developmental milestones phenotype. Molecular analysis found variants predicted to be pathogenic in 5 / 16 cases (31.2%). Among these mutations, two were previously reported: MAP2K1-c.389A>G (p.Tyr130Cys) and PTPN11 - c.1510A>G (p.Met504Val); three are novel: CBL-c.2520T>G (p.Cys840Trp), PTPN11- c.1496C>T (p.Ser499Phe), and MAP2K1- c.200A>C (p.Asp67Ala). Molecular dynamic simulations indicated that novel variants identified impact the stability and flexibility of their corresponding proteins. Genotype-phenotype correlations showed that clinical features of NS were more typical in patients with variants in MAP2K1. This first application of targeted NGS for the molecular diagnosis of NS in South Africans suggests that, while there is no major phenotypic difference compared to other populations, the distribution of genetic variants in NS in South Africans may be different. Frontiers Media S.A. 2019-04-16 /pmc/articles/PMC6477999/ /pubmed/31057598 http://dx.doi.org/10.3389/fgene.2019.00333 Text en Copyright © 2019 Tekendo-Ngongang, Agenbag, Bope, Esterhuizen and Wonkam. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Tekendo-Ngongang, Cedrik
Agenbag, Gloudi
Bope, Christian Domilongo
Esterhuizen, Alina Izabela
Wonkam, Ambroise
Noonan Syndrome in South Africa: Clinical and Molecular Profiles
title Noonan Syndrome in South Africa: Clinical and Molecular Profiles
title_full Noonan Syndrome in South Africa: Clinical and Molecular Profiles
title_fullStr Noonan Syndrome in South Africa: Clinical and Molecular Profiles
title_full_unstemmed Noonan Syndrome in South Africa: Clinical and Molecular Profiles
title_short Noonan Syndrome in South Africa: Clinical and Molecular Profiles
title_sort noonan syndrome in south africa: clinical and molecular profiles
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477999/
https://www.ncbi.nlm.nih.gov/pubmed/31057598
http://dx.doi.org/10.3389/fgene.2019.00333
work_keys_str_mv AT tekendongongangcedrik noonansyndromeinsouthafricaclinicalandmolecularprofiles
AT agenbaggloudi noonansyndromeinsouthafricaclinicalandmolecularprofiles
AT bopechristiandomilongo noonansyndromeinsouthafricaclinicalandmolecularprofiles
AT esterhuizenalinaizabela noonansyndromeinsouthafricaclinicalandmolecularprofiles
AT wonkamambroise noonansyndromeinsouthafricaclinicalandmolecularprofiles